CTI BioPharma waiting $10 million milestone from Teva for FDA approving Trisenox for certain leukemia

CTI BioPharma is expecting $10 million milestone in February, 2018 from Teva, related to a milestone for U.S. Food and Drug Administration approval of TRISENOX (arsenic trioxide) for first line treatment of acute promyelocytic leukemia. 

The company said that milestone will be paid pursuant to an acquisition agreement for Trisenox previously entered into with Teva under which CTI BioPharma is eligible to receive up to an additional $50 million in payments upon achievement by Teva of specified sales and development milestones related to Trisenox.